Background: Measurement of rivaroxaban efficacy using the rivaroxaban-specific anti-Xa assay (raXa) can be used for monitoring in veterinary medicine. Detection of rivaroxaban efficacy using other hemostatic tests would make monitoring timelier and more accessible.
Objectives: Compare results of raXa with prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen concentration, tissue factor (TF) and kaolin-activated thromboelastography (TEG), and thrombin generation (TG) in hypercoagulable dogs.
Animals: Twelve client-owned dogs, diagnosed with hypercoagulability or thromboembolic disease, and prescribed rivaroxaban, were recruited from a tertiary referral hospital from 2020 to 2022.
Methods: Prospective clinical trial. Jugular vein blood samples were collected before treatment, and 1 week and 1-3 months after initiation of rivaroxaban therapy. Hemostatic tests were performed at each visit (3 h after rivaroxaban dosing). TG curve parameters lag time, endogenous thrombin potential (ETP), peak, and time to peak (ttpeak) were assessed.
Results: There was a significant linear relationship between raXa and PT (r = 0.74, p < 0.001), ETP (r = 0.83, p < 0.001), lag time (r = 0.87, p < 0.001), peak (r = 0.86, p < 0.001), and ttpeak (r = 0.86, p < 0.001). There was a weak linear relationship between raXa and kaolin-activated TEG parameter reaction time (R) (r = 0.49, p = 0.026). There was no significant relationship between raXa and aPTT, fibrinogen concentration and the remainder of the TEG variables (p > 0.05).
Conclusion And Clinical Importance: PT and TG correlated with raXa. PT performed at a reference laboratory appeared to be a convenient method to monitor a small cohort of dogs receiving rivaroxaban therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836667 | PMC |
| http://dx.doi.org/10.1111/jvim.70014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 71-Year-Old Man With Gas Accumulation in the Left Atrium.
Chest
March 2025
Department of Intensive Care Medicine, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.
A 71-year-old man with a history of atrial fibrillation presented to the emergency department with sudden unconsciousness after finishing lunch. Just 4 weeks ago, the patient underwent radiofrequency ablation for atrial fibrillation and regularly took rivaroxaban for anticoagulant therapy. According to the medical history, the patient suffered recurrent chest tightness and heartburn after radiofrequency ablation without other discomforts.
View Article and Find Full Text PDFHow to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
J Thromb Haemost
March 2025
MAHSC Professor, University of Manchester, Oxford Road, Manchester, United Kingdom.
Monitoring unfractionated heparin (UFH) to ensure effective anticoagulation may be performed using anti-factor Xa activity (anti-Xa) instead of the activated partial thromboplastin time. However, in patients who have been treated with oral factor Xa (FXa) inhibitors (apixaban, rivaroxaban, and edoxaban) while switching to UFH therapy, there is a risk that these oral anti-FXa drugs could interfere with UFH calibrated anti-Xa monitoring. This may lead to inappropriate anticoagulation management.
View Article and Find Full Text PDFThe novel SERPINC1 missense mutation c.1148 T > A (p.L383H) causes hereditary antithrombin deficiency and thromboembolism in a Chinese family: a case report.
J Med Case Rep
March 2025
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Background: Hereditary antithrombin deficiency, an autosomal-dominant thrombotic disease caused by a SERPINC1 gene deficiency, is extremely rare, although it is the leading cause of hereditary thrombophilias. Herein we report a novel SERPINC1 gene mutation in a Chinese family and one case of pulmonary embolism associated with the mutation. We also discuss the latest diagnostic and treatment strategies for antithrombin deficiency.
View Article and Find Full Text PDFRSM and AI based machine learning for quality by design development of rivaroxaban push-pull osmotic tablets and its PBPK modeling.
Sci Rep
March 2025
Department of Pharmaceutics & Bioavailability and Bioequivalence Research Facility, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, 75270, Pakistan.
The study is based on applying Artificial Neural Network (ANN) based machine learning and Response Surface Methodology (RSM) as simultaneous bivariate approaches in developing controlled-release rivaroxaban (RVX) osmotic tablets. The influence of different types of polyethylene oxide, osmotic agents, coating membrane thickness, and orifice diameter on RVX release profiles was investigated. After obtaining the trial formulation data sets from Central Composite Design (CCD), an ANN-based model was trained to get the optimized formulations.
View Article and Find Full Text PDFTriple antithrombotic therapy or 'triple therapy' describes the combination of 3 oral antithrombotic medications - an anticoagulant drug (warfarin, apixaban, rivaroxaban or dabigatran) and 2 antiplatelet drugs (usually aspirin plus clopidogrel). Most commonly, triple therapy is indicated for patients who require dual antiplatelet therapy following coronary stent insertion for acute coronary syndrome and long-term anticoagulation for atrial fibrillation. Current evidence supports shorter durations of triple therapy to mitigate bleeding risks without compromising ischaemic protection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!